FX-7742

FX-7742 is a small molecule drug candidate developed by Felicitex Therapeutics, primarily for the treatment of non-small cell lung cancer (NSCLC). According to company pipeline information, the drug is designed to target the KRAS G12C mutation, a common oncogenic driver in lung cancer. However, some research contexts also identify FX-7742 as an inhibitor of DYRK1B (dual specificity tyrosine phosphorylation regulated kinase 1B), a kinase that allows cancer cells to enter or remain in a dormant state. By inhibiting these targets, FX-7742 aims to disrupt tumor cell proliferation and eliminate dormant cancer cells that contribute to treatment resistance and recurrence. As of 2022, the compound was in preclinical development, with efforts focused on chemistry, manufacturing, and control (CMC) and safety profiling to support an Investigational New Drug (IND) filing.